Most Recent

image: Thermo Fisher to Acquire Affymetrix

Thermo Fisher to Acquire Affymetrix

By | January 11, 2016

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.

0 Comments

image: Disease-Linked Genes Questioned

Disease-Linked Genes Questioned

By | January 6, 2016

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.

0 Comments

image: TS Picks: CRISPR Patent Edition

TS Picks: CRISPR Patent Edition

By | January 5, 2016

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.

3 Comments

image: CRISPR Improves Disease in Adult Mice

CRISPR Improves Disease in Adult Mice

By | January 4, 2016

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.

1 Comment

image: Pluripotency Bots

Pluripotency Bots

By | January 1, 2016

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.

0 Comments

image: All Together Now

All Together Now

By | January 1, 2016

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.

1 Comment

image: Contributors

Contributors

By | January 1, 2016

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.

0 Comments

image: Managing Methylation

Managing Methylation

By | January 1, 2016

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.

0 Comments

image: Reveling in the Revealed

Reveling in the Revealed

By | January 1, 2016

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.

2 Comments

image: Speaking of Science

Speaking of Science

By | January 1, 2016

The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.

0 Comments

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech